Clinical Trials on Advanced Lung Adenocarcinoma

Total 73732 results

1
2
3
4
5
6
7
8
9
10
...
1474
1475
›

The University of Texas Health Science Center at...
National Cancer Institute (NCI)

Recruiting

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Advanced Lung Adenocarcinoma

United States
Simcere Pharmaceutical Co., Ltd

Unknown

The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar

Advanced Primary Lung Adenocarcinoma

China
Grit Biotechnology

Recruiting

Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients with Advanced Lung Adenocarcinoma

Advanced Lung Adenocarcinoma；Adult

China
China Medical University Hospital

Completed

Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect

Advanced Lung Adenocarcinoma
Marina Garassino

Recruiting

Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma (FAME)

Advanced LKB1-inactive Lung Adenocarcinoma

Italy
Emory University
National Cancer Institute (NCI)

Recruiting

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Adenocarcinoma | Refractory Lung Adenocarcinoma

United States
BeiGene

Recruiting

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Advanced Colorectal Cancer | Metastatic Solid Tumors | Advanced Gastric Cancer | Advanced Non-squamous Non-small-cell Lung Cancer | Advanced Pancreatic Ductal Adenocarcinoma | Advanced Esophageal Adenocarcinoma | Advanced Gastroesophageal Junction Cancer

China, Australia, United States, New Zealand, Korea, Republic of, Spain
Kyowa Kirin Co., Ltd.
Kyowa Kirin, Inc.

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Japan
University of California, Los Angeles
University of California, San Francisco; University of California, Irvine

Completed

UC Health Care Planning Study

Advanced Cancer | Advance Care Planning | Advance Directives

United States
Context Therapeutics Inc.

Recruiting

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Colorectal Cancer | Epithelial Ovarian Cancer | Cholangiocarcinoma Non-resectable | Lung Adenocarcinoma Metastatic | Malignant Pleural Mesothelioma, Advanced | Cholangiocarcinoma Advanced | Pancreatic Adenocarcinoma Advanced or Metastatic | Mesothelin-positive Advanced Malignant Solid Tumors | Mesothelin-expressing... and other conditions

United States
Groupe Hospitalier Paris Saint Joseph

Withdrawn

Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas (NTS)

Metastatic Lung Adenocarcinomas
Northwestern University
National Cancer Institute (NCI)

Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer... and other conditions

United States
Fujian Medical University Union Hospital

Not yet recruiting

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

Neoadjuvant Therapy | ALK-positive Advanced NSCLC | ALK-positive Non-small Cell Lung Cancer (NSCLC) | MPR

China
Astellas Pharma Global Development, Inc.

Available

Early Access Program for Zolbetuximab

Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma Cancer

Germany, United States, Brazil, France, Korea, Republic of, Singapore
AstraZeneca

Recruiting

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)

Non-Small Cell Lung Cancer (NSCLC) | Advanced Solid Tumours | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

Canada, Spain, United Kingdom, Italy, Belgium, Korea, Republic of, Poland, Australia, China, Thailand, United States, Japan, Turkey, Netherlands, Hong Kong
Astellas Pharma Korea, Inc.

Recruiting

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Korea, Republic of
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Advanced Solid Tumor | Advanced Gastric Carcinoma | Advanced Cholangiocarcinoma | Advanced Lung Cancer

China
National Taiwan University Hospital

Not yet recruiting

The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.

Quality of Life | Lung Neoplasms | Lung Cancer | Exercise | Lung Adenocarcinoma | Psychological Distress | Pulmonary Rehabilitation | Self Efficacy | Advanced Lung Cancer | Lung Tumor
Mayo Clinic

Recruiting

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients with Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Primary Peritoneal Clear Cell Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Advanced Fallopian Tube Carcinoma | Advanced... and other conditions

United States
Changhai Hospital
CARsgen Therapeutics Co., Ltd.

Unknown

Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma | Advanced Gastric Adenocarcinoma

China
Shen Lin
RemeGen Co., Ltd.

Not yet recruiting

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Advanced Solid Tumor | Advanced Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma | HER2

China
Wuhan Union Hospital, China

Recruiting

Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC

Advanced Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma

China
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Pancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma

United States
Tianhong Li
National Cancer Institute (NCI); LabyRx Immunologic Therapeutics

Recruiting

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Adenocarcinoma | Advanced Adenocarcinoma | Recurrent Adenocarcinoma

United States
Ikena Oncology
Gilead Sciences

Terminated

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Gastric Adenocarcinoma | Lung Adenocarcinoma | Advanced Solid Tumor

United States
Chinese PLA General Hospital

Recruiting

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Advanced Gastroesophageal Adenocarcinoma

China
Yonsei University

Completed

PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma

Advanced Gastric Adenocarcinoma

Korea, Republic of
Renmin Hospital of Wuhan University

Completed

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC (RENMIN-213)

Advanced Gastric Adenocarcinoma

China
UNICANCER
Summit Therapeutics

Not yet recruiting

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma (GRACIE)

Metastatic Gastric Adenocarcinoma | Advanced Gastric Adenocarcinoma | Metastatic Esophageal Adenocarcinoma | Advanced Esophageal Adenocarcinoma

France
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
SystImmune Inc.

Not yet recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Other Solid Tumors | Advanced Pancreatic Ductal Adenocarcinoma | Mucinous Ovarian Adenocarcinoma
Shanghai Longyao Biotechnology Inc., Ltd.
The Affiliated Hospital of Xuzhou Medical University

Recruiting

A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma

Advanced Gastric Adenocarcinoma

China
Samsung Medical Center

Completed

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
Samsung Medical Center

Completed

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
Samsung Medical Center

Completed

Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
Samsung Medical Center

Terminated

Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy

Advanced Gastric Adenocarcinoma

Korea, Republic of
Duke University
National Cancer Institute (NCI)

Recruiting

Engage Psychosocial Intervention for Cancer Symptoms (Engage)

Advanced Breast Cancer | Advanced Prostate Cancer | Advanced Colorectal Carcinoma | Advanced Lung Cancer | Advanced Colorectal Adenocarcinoma

United States
PanTher Therapeutics

Recruiting

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma

United States
Multitude Therapeutics Inc.
Tigermed Consulting Co., Ltd

Recruiting

AMT-151 in Patients With Selected Advanced Solid Tumours

Ovarian Cancer | Ovarian Epithelial Cancer | Lung Adenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Endometrial Cancer | Advanced Cancer | Ovarian Clear Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial... and other conditions

China, Australia
Nanfang Hospital, Southern Medical University

Not yet recruiting

An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.

Advanced Colorectal Adenocarcinoma
Henan Cancer Hospital

Recruiting

A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab

Advanced Gastric Adenocarcinoma

China
Veru Inc.

Terminated

To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer (VERU-100)

Advanced Prostate Adenocarcinoma

United States
Samsung Medical Center

Completed

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Advanced Gastric Adenocarcinoma

Korea, Republic of
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Japan
Sir Run Run Shaw Hospital

Recruiting

Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma

Advanced Pancreatic Ductal Adenocarcinoma

China
Xijing Hospital

Recruiting

Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Jules Bordet Institute

Completed

Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C) (RegARd-C)

Advanced Chemorefractory Colorectal Adenocarcinoma

Belgium

1
2
3
4
5
6
7
8
9
10
...
1474
1475
›

Clinical Trials on Advanced Lung Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations